PRESCIENT – PET ResponSe CrItEria for Neuroendocrine Tumors
Lisa Bodei, MD, PhD
Active Projects
PRMT5 inhibitor: next option for neuroendocrine tumors?
Thomas Walter, MD, PhD
Reconstructing the evolutionary history of neuroendocrine tumor subtypes
Nicolas Alcala, PhD
Role of Nrf2 in SBNET drug resistance and development of a novel inhibitor
Po Hien Ear, PhD
Role of the peripheral nervous system in pancreatic neuroendocrine tumors
William Hwang, MD, PhD
Role of YAP and TAZ restriction in Merkel Cell Carcinoma development
Chiara Mazziotta, PhD
Targeted delivery of DNA repair-inhibiting drugs to GEP-NETs
Susanne Kossatz, PhD
Targeting lipid metabolism in gastroenteropancreatic neuroendocrine tumors
Yuanyuan Qiao, PhD
Targeting the Epigenetic Landscape of GEP-NETs through Menin-MLL Inhibition
Suzann Duan, PhD
Theranostic anti-SSTR2 CAR T-cell Therapy for Neuroendocrine Tumors
Carolin Kitzberger, PhD